



POSTER PRESENTATION

Open Access

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization

L Heyndrickx^{1*}, G Stewart-Jones², H Schuitemaker³, E Bowles², L Buonaguro⁴, M Jansson⁵, B Grevstad⁶, L Vinner⁶, M Ramaswamy⁷, P Biswas⁸, G Scarlatti⁸, G Vanham¹, A Fomsgaard⁶

From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012

Background

Eliciting broad cross neutralizing antibodies (bNAb) remains the primary and most challenging goal in HIV-1 vaccine development. So far no vaccine candidate has induced such bNAb. Selecting Env vaccine candidates will require both antigenic and immunogenic optimization and testing in relevant animal models.

Methods

Based on in-vitro neutralizing activity in serum, patients (n=6, subtype A and B infected) were selected and Env sequences of early HIV-1 variants, still sensitive to autologous neutralization, were used to generate soluble Env as immunogens. Gp140 trimeric proteins were expressed (293T cells) and purified. Rabbits (4/group) were immunized s.c. at weeks 0, 2, 4, 8 with 100µg trimer adjuvanted with cationic CAF01. Control groups received 20µg and 100µg trimer plus/minus CAF01 respectively. Sera collected at weeks 0, 2, 4, 8, 12 and 14 were screened in gp120-IIIB ELISA and IgG was analyzed in the TZMbl neutralization assay.

Results

All rabbits generated a gp120-IIIB specific IgG response 2 weeks after the first immunization and titers were boosted after each subsequent immunization. IgG titers measured 4 weeks after the last immunization clearly differed between groups (n=5) receiving 100µg/immunization (Geometric mean titer (GMT) : 152.601) and the group receiving 20µg/immunization (GMT : 13.262) or the group omitting CAF01 (GMT : 27.262). Only IgG from rabbits receiving the highest dose and in the

presence of CAF01 were able to neutralize Tier 1 pseudoviruses of different subtypes.

Neutralizing activity was detected after the 2nd immunization and was boosted after each immunization. No significant differences were observed between the different trimers.

Conclusion

Gp140 trimers based on HIV-1 variants of patients with bNAb in serum elicited gp120-IIIB specific IgG and NAb given that enough immunogen was administered in the presence of CAF01. These results indicate that the development of HIV-1 Env specific NAb is dose dependent and strengthen the rabbit model for HIV vaccine studies.

Author details

¹Institute of Tropical Medicine, Antwerp, Belgium. ²Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK. ³Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. ⁴Istituto Nazionale Tumori "Fond. G. Pascale", Naples, Italy. ⁵Department of Laboratory Medicine, University of Lund, Lund, Sweden. ⁶Statens Serum Institut, Copenhagen, Denmark. ⁷National Institute for Biological Standards and Control, Hertfordshire, UK. ⁸DIBIT - San Raffaele Scientific Institute, Milan, Italy.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P17

Cite this article as: Heyndrickx *et al.*: Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization. *Retrovirology* 2012 **9** (Suppl 2):P17.

¹Institute of Tropical Medicine, Antwerp, Belgium
Full list of author information is available at the end of the article